Eli Lilly (NYSE: LLY) began a roll in late 2020 that lasted almost four years. This decline includes a sell-off earlier this ...
Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 472.57% and ...
Guggenheim lowered the firm’s price target on Eli Lilly (LLY) to $973 from $995 and keeps a Buy rating on the shares. The firm is updating its ...
Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...
Omvoh (mirikizumab-mrkz) for moderately to severely active Crohn’s disease in adults. Omvoh is now approved in the U.S. for ...
Turning to 2025 guidance, Lilly noted that new medicines and new uses of existing medicines, expansion of production, and ...
Unfortunately for the company, however, the early glimpse at its fourth-quarter performance doesn’t seem to be going over ...
(Reuters) -Eli Lilly said on Monday it plans to buy Scorpion Therapeutics' experimental cancer therapy for up to $2.5 billion ...
Eli Lilly ( LLY -6.59%) is the most valuable healthcare stock in the world, with a market capitalization of around $720 ...
Eli Lilly and Company (LLY) announced on Tuesday that the pharmaceuticals company expects Q4 2024 revenue to be ~$13.5B.
Medical industry giants Eli Lilly and Merck will collaborate with Purdue through a new institute, which aims to advance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback